1. Home
  2. MESO vs DEI Comparison

MESO vs DEI Comparison

Compare MESO & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.51

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$10.71

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
MESO
DEI
Founded
2004
1971
Country
Australia
United States
Employees
81
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
MESO
DEI
Price
$15.51
$10.71
Analyst Decision
Strong Buy
Hold
Analyst Count
1
8
Target Price
N/A
$12.94
AVG Volume (30 Days)
212.7K
2.0M
Earning Date
02-26-2026
05-05-2026
Dividend Yield
N/A
7.22%
EPS Growth
N/A
N/A
EPS
N/A
0.09
Revenue
N/A
$1,003,982,000.00
Revenue This Year
$629.74
$1.70
Revenue Next Year
$30.65
$2.35
P/E Ratio
N/A
$116.78
Revenue Growth
N/A
1.77
52 Week Low
$9.88
$9.04
52 Week High
$21.50
$16.94

Technical Indicators

Market Signals
Indicator
MESO
DEI
Relative Strength Index (RSI) 50.91 65.70
Support Level $14.44 $9.17
Resistance Level $16.37 $11.22
Average True Range (ATR) 0.48 0.32
MACD 0.10 0.13
Stochastic Oscillator 61.26 81.69

Price Performance

Historical Comparison
MESO
DEI

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.

Share on Social Networks: